Mediware Information Systems, Inc. (/exchange>NASDAQ/exchange>>/>: MEDW) announced today that the Blood Bank of Alaska is the latest major blood center to license LifeTrak®, the company's 510(k) cleared blood donor management software. Using LifeTrak, the blood center plans to integrate core software systems, launch an additional mobile unit and increase the number of advanced collection machines, to help the center to more efficiently collect more blood products. Going forward, the blood center plans to launch additional Mediware technologies, such as RecruitTrak™, to help the blood center offer incentive programs to current donors.
"LifeTrak is a part of an expansion strategy that will help our teams, processes and technology operate at top performance to achieve our five year strategic goals," said Margaret Baker, Blood Bank of Alaska's chief operating officer. "It is a modern technology platform that allows us to expand services in our lab, integrate key systems and bring together complex processes that are critical to our organization."
The Blood Bank of Alaska was established in 1962 and has grown dramatically to support the state's growing population and advances in medical and surgical care. It currently supports more than 25 hospitals and medical centers throughout Alaska and last year collected more than 25,000 units.
"A benefit of having Mediware as our core technology is the fact that we can deploy additional software products to increase our capabilities and broaden our donor recruiting and retention programs," continued Ms. Baker. "These will be critical to expanding our reach and enhancing future growth."
LifeTrak is a 510(k) cleared donor management system that manages donor eligibility, manufacturing and distribution for many of the largest blood suppliers, testing facilities, centralized transfusion services (CTS) and large hospital donor programs. LifeTrak 4.0, which was made available in 2009, delivers increased flexibility through a web based deployment. LifeTrak 4.x is also fully compliant with the newly developed U.S. Biovigilance Network which tracks blood collections and use.